

Hepatocyte Nuclear Factor 1, a Transcription Factor at the Crossroads of Glucose Homeostasis

MARCO PONTOGLIO

Oncogenic Virus Unit, CNRS URA 1644, Biotechnology Department, Pasteur Institute, Paris, France.

Abstract. Hepatocyte nuclear factor 1 (HNF1) is a transcription factor involved in the regulation of a large set of hepatic genes, including albumin, β -fibrinogen, and α 1-antitrypsin. HNF1 is expressed in the liver, digestive tract, pancreas, and kidney. Mice lacking HNF1 exhibit hepatic, pancreatic, and renal dysfunctions. HNF1-deficient mice fail to express the hepatic phenylalanine hydroxylase gene, giving rise to hyperphenylalaninemia. Renal proximal tubular reabsorption of glucose, phosphate, arginine, and other metabolites is affected, produc-

ing severe renal glucosuria, phosphaturia, and amino aciduria. Homozygous mutant mice also exhibit a dramatic insulin secretion defect. This dysfunction resembles that exhibited by patients with maturity-onset diabetes mellitus of the young type 3, who carry mutations in the human HNF1 gene in the heterozygous state. These data show that HNF1 is a major regulator of glucose homeostasis, regulating the expression of genes that are expressed in the liver, kidney, and pancreas.

Cell differentiation is a rather elaborate program that is regulated largely at the transcriptional level. In this context, the concerted action of a limited number of transcription factors allows the selective activation of cell-specific genes. The study of transcription control regions of genes preferentially expressed in hepatocytes has led to the identification of several nuclear proteins that play important roles in liver-specific transcription. This set of transcription factors includes hepatocyte nuclear factor 1 (HNF1) and variant HNF1 (vHNF1) (also known as HNF1 α and HNF1 β or LF-B1 and LB-B3, respectively) (1–5), HNF3 α , $-\beta$, and $-\gamma$ (6), HNF4 (7), and HNF6 (8). HNF1 was first identified as a DNA-binding activity capable of interacting with the promoter of several hepatic genes, including albumin, α 1-antitrypsin, and β -fibrinogen. HNF1 is a dimeric protein functionally composed of three domains, *i.e.*, an amino-terminal dimerization domain composed of 33 amino acids, a DNA-binding domain belonging to the homeobox family, and a carboxyl-terminal domain that is essential for transactivation of target promoters.

Among vertebrates, the closely related protein vHNF1 has also been characterized (4,5). HNF1 and vHNF1 share strong homologies in both the dimerization domain and the DNA-binding domain. These homologies enable the two proteins to form heterodimers and bind to the same DNA sequences. However, HNF1 seems to be a more potent transactivator than is vHNF1 in transient transfection assays. Another partner for HNF1, termed the dimerization cofactor for HNF1, has also been cloned (9). This protein binds to the amino-terminal

domain of both HNF1 and vHNF1, stabilizing the homo- and heterodimers and somewhat increasing their transactivation potential. Surprisingly, the dimerization cofactor for HNF1 has also been shown to be involved in the enzymatic dehydration of pterin-4 α -carbinolamine to dihydrobiopterin, a cofactor involved in the enzymatic hydroxylation of phenylalanine and tryptophan (10,11).

Studies have shown that HNF1 and vHNF1 are expressed in polarized epithelia of different organs, including the liver, digestive tract, pancreas, and kidney (12–15). The expression of vHNF1 overlaps with that of HNF1 with the exception of lung, where only vHNF1 is expressed. Conversely, vHNF1 is very weakly expressed in liver, where HNF1 constitutes >95% of the total HNF1-like protein. In other organs, HNF1 and vHNF1 are more or less equally expressed. In the kidney, HNF1 expression is confined to proximal tubules. In fact, immunofluorescence studies show that HNF1-positive nuclei are observed only in tubules that are also positive for villin, a marker of proximal tubules (Figure 1). In contrast, vHNF1 is also expressed in distal tubules (12–15).

A significant difference between HNF1 and vHNF1 is the onset of their expression during embryonic development. vHNF1 is expressed in the extraembryonic visceral endoderm, in the neural tube, and in the primitive gut at a developmental stage when HNF1 expression has not yet been turned on (16–18). In fact, HNF1 expression is activated only during organogenesis. Again, during liver and renal development, vHNF1 is expressed from the first stages of organogenesis, whereas HNF1 is turned on later, when differentiation is more advanced. For example, during kidney development, vHNF1 is already activated in the swelling ureteric bud and in the surrounding metanephric mesenchyme, whereas HNF1 becomes detectable during formation of the S-shaped structures (19). The differences between HNF1 and vHNF1 in their expression patterns and timing during development are also reflected in the outcomes of gene knockout experiments in mice. Although

Correspondence to Dr. Marco Pontoglio, Unité des Virus Oncogènes, CNRS URA 1644, Département des Biotechnologies, Institut Pasteur, 25, rue du Dr Roux, 75724 Paris Cedex 15, France. Phone: 33 1 456 88514; Fax: 33 1 406 13033; E-mail: marcop@pasteur.fr

1046-6673/1111-0140

Journal of the American Society of Nephrology

Copyright © 2000 by the American Society of Nephrology




Figure 1. Localization of hepatocyte nuclear factor 1 (HNF1) in kidney. Cryosections from mouse kidneys were labeled by indirect immunofluorescence staining with antibodies against HNF1 (antibody TC284) (34) (green) and antibodies against villin (kindly provided by Silvie Robine, Institut Curie, CNRS UMR 144, Paris, France) (red).

vHNF1^{-/-} mice embryos die at day 6.5 to 7.0 after conception, because of a defect in extraembryonic visceral endoderm differentiation (17,18), disruption of the mouse HNF1 gene leads to a complex set of postnatal dysfunctions that affect most of the organs in which HNF1 is expressed (13). HNF1^{-/-} mice do not die as embryos but exhibit hepatic, pancreatic, and renal dysfunctions that significantly affect the growth and life spans of the mutant animals.

Liver Dysfunction

HNF1-deficient mice exhibit significant liver enlargement. Analysis of plasma biochemical parameters revealed extensive hypercholesterolemia and hyperphenylalaninemia. The catabolism of phenylalanine, an essential amino acid, includes an obligatory step involving the conversion of phenylalanine to tyrosine. This hydroxylation reaction is catalyzed by phenylalanine hydroxylase (PAH), an enzyme that is normally expressed in liver and to a lesser extent in kidney. Mutations in the human PAH gene can compromise this enzymatic activity and provoke the accumulation of phenylalanine in the plasma, giving rise to the phenylketonuric syndrome (20). Analysis of the expression of the murine PAH gene in HNF1^{-/-} animals demonstrated that this gene was totally silent (13). This result was surprising, because all other known HNF1 targets, such as albumin, α 1-antitrypsin, and β -fibrinogen, exhibited only moderate decreases (two- to fourfold) in their transcription rates. The corollary of these observations is that the lack of

HNF1 results in selective and drastic inactivation of only a small subset of hepatic genes. The PAH gene, which is normally responsive to glucocorticoids and cAMP, cannot be induced by any hormonal treatment in the liver of HNF1-deficient animals (21). This lack of inducibility is probably attributable to the fact that the PAH gene in the hepatocytes of HNF1-deficient mice is characterized by an inactive chromatin structure in which several nuclease-hypersensitive sites, located in the transcription control regions of the PAH gene, have disappeared. These nuclease-sensitive sites contain several HNF1-binding sites and should play an important role in the transcriptional activation of the PAH gene. In addition to the poorly accessible chromatin status, PAH transcription control regions are characterized by hypermethylation of CpG residues in the DNA sequence. Therefore, the lack of HNF1 prevents remodeling and demethylation of the PAH locus. In this context, HNF1 seems to play an essential role by inducing chromatin remodeling events that render the transcription control region of the PAH gene accessible to the transcription machinery. It will be important to elucidate the mechanisms involved in the HNF1-dependent demethylation and chromatin remodeling processes.

In the kidney, where relatively high levels of vHNF1 persist in HNF1^{-/-} mice, the normal low expression level of PAH is not affected. This suggests that vHNF1 might have taken over the role of HNF1 for this function in the kidney.

Kidney Dysfunction

HNF1-deficient mice exhibit drastic reductions in the proximal reabsorption of several metabolites. The vast majority of filtered glucose, as well as phosphate and some specific amino acids such as arginine, are abundantly lost in the urine, instead of being reabsorbed by the proximal tubules (13). The relative high concentrations of glucose and other metabolites induce osmotic diuresis, which causes the animals to become polyuric and polydipsic. The reabsorption of most of these metabolites is based on secondary active transport performed by Na⁺-dependent cotransporters. The driving force for this transport is the electrochemical gradient of Na⁺ across the luminal membrane of proximal tubular cells.

Phlorizine, which is a glucoside capable of inhibiting glucose reabsorption, is able to bind irreversibly to glucose cotransporters. The use of this inhibitor has demonstrated that brush border membranes of HNF1^{-/-} animals exhibit large decreases in the number of phlorizine-binding sites (13). Glucose reabsorption is accomplished by two distinct cotransporters, termed sodium glucose transporter type 1 (SGLT1) and SGLT2 (22–25). SGLT2 is preferentially expressed in the initial portion (S1 and S2) of proximal tubules. There the concentration of glucose is still relatively high and SGLT2 is responsible for so-called high-capacity/low-affinity glucose transport. In the more distal part of the proximal tubule (S3), the glucose concentration is decreased and SGLT1, which is preferentially expressed in this segment, performs low-capacity/high-affinity transport. SGLT1 and SGLT2 have different glucose/Na⁺ stoichiometries (1:2 and 1:1 for SGLT1 and SGLT2, respectively) (20). This enables SGLT1 to reabsorb glucose against the much stronger glucose gradient that is characteristic of the more distal part of proximal tubules.

Northern blot analysis of renal mRNA has demonstrated that SGLT1 is normally expressed, whereas transcription of the SGLT2 gene is severely affected, in the kidneys of HNF1-deficient animals (26). In addition, isolated tubules are characterized by a reduced capacity to reabsorb glucose, phosphate, and arginine but not alanine, an amino acid that is reabsorbed normally *in vivo* in HNF1^{-/-} animals (unpublished results).

Pancreas Dysfunction

Mutations in the human HNF1 gene, in the heterozygous state, have been found to be responsible for a particular form of diabetes mellitus termed maturity-onset diabetes mellitus of the young type 3 (MODY3) (27). Affected patients are characterized by an insulin secretion defect that becomes apparent before 25 yr of age (28,29). The blood glucose levels of HNF1^{+/-} mice are completely normal and those of HNF1-deficient mice are not particularly elevated; however, the severe renal glucosuria that affects mutant homozygous mice could have masked an insulin secretion defect. In fact, *in situ* glucose pancreas perfusion experiments demonstrated that pancreata from mutant mice are strongly affected in their capacity to secrete insulin in response to glucose (30). However, insulin is secreted when depolarizing solutions of KCl are perfused, indicating that the Langerhans islets of HNF1-deficient animals still produce insulin but their β -cells have a major defect

in glucose-sensing. In addition, metabolic studies have demonstrated that the flux of glucose through glycolysis in islets from mutant mice is reduced, producing blunted increases in ATP levels in response to glucose exposure (31).

HNF1-deficient mice exhibit defective insulin secretion as well as a major defect in renal glucose reabsorption. The combination of these two dysfunctions establishes a novel dynamic equilibrium for glucose homeostasis. Renal glucosuria at least partially compensates for the defective insulin secretion.

MODY3 Mutations

MODY3 in human patients is inherited in a dominant manner, whereas the dysfunctions observed in HNF1^{-/-} mice are transmitted as a recessive trait. In fact, HNF1^{+/-} heterozygous mice do not exhibit any insulin secretion defect or glucose intolerance. This still-unresolved paradox is also observed for another form of diabetes mellitus. Mutations in the human HNF4 gene result in the MODY1 diabetic phenotype (32). Again, affected patients are heterozygous, whereas heterozygous mice carrying a mutation are perfectly normal (33). To date, >80 independent mutations have been identified in patients with MODY3. Analysis of these mutations has demonstrated that some of them render the protein very unstable and poorly expressed (because it is rapidly degraded) (34). Other mutations affect either DNA binding or transactivation potential. Finally, a subgroup of mutations exert a dominant-negative effect over the wild-type protein. However, patients with the latter type of mutation do not exhibit a more severe phenotype (34). In mice, it is possible that just one copy of either the HNF1 or HNF4 wild-type gene is sufficient to accomplish the functions exerted by the transcription factors. In contrast, in patients with MODY1 or MODY3, the presence of just one copy of HNF4 or HNF1 could lead to a haploid insufficiency in the pancreas in adulthood.

Conclusion

HNF1 plays an important role in controlling the postnatal functions of the liver, pancreas, and kidney. The phenotype of HNF1^{-/-} mice has revealed that this transcription factor is crucial for the transcriptional activation of genes that play key roles in phenylalanine catabolism, pancreatic β -cell glucose-sensing, and renal proximal tubular reabsorption of glucose and several other metabolites. For these reasons, HNF1 can be considered a transcription factor at the crossroads of the regulation of glucose homeostasis.

References

1. Frain M, Swart G, Monaci P, Nicosia A, Stampfli S, Frank R, Cortese R: The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. *Cell* 59: 145–157, 1989
2. Baumhueter S, Mendel DB, Conley PB, Kuo CJ, Turk C, Graves MK, Edwards CA, Courtois G, Crabtree GR: HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF. *Genes Dev* 4: 372–379, 1990
3. Chouard T, Blumenfeld M, Bach I, Vandekerckhove J, Cereghini S, Yaniv M: A distal dimerization domain is essential for DNA-binding by the atypical HNF1 homeodomain. *Nucleic Acids Res* 18: 5853–5863, 1990
4. Rey-Campos J, Chouard T, Yaniv M, Cereghini S: vHnf1 is a

- homeoprotein that activates transcription and forms heterodimers with Hnf1. *EMBO J* 10: 1445–1457, 1991
5. De Simone V, De Magistris L, Lazzaro D, Gerstner J, Monaci P, Nicosia A, Cortese R: LFB3, a heterodimer-forming homeoprotein of the LFB1 family, is expressed in specialized epithelia. *EMBO J* 10: 1435–1443, 1991
 6. Lai E, Prezioso VR, Smith E, Litvin O, Costa RH, Darnell JE Jr: HNF-3A, a hepatocyte-enriched transcription factor of novel structure, is regulated transcriptionally. *Genes Dev* 4: 1427–1436, 1990
 7. Sladek FM, Zhong WM, Lai E, Darnell JE Jr: Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. *Genes Dev* 4: 2353–2365, 1990
 8. Lemaigre FP, Durviaux SM, Truong O, Lannoy VJ, Hsuan JJ, Rousseau GG: Hepatocyte nuclear factor 6, a transcription factor that contains a novel type of homeodomain and a single cut domain. *Proc Natl Acad Sci USA* 93: 9460–9464, 1996
 9. Mendel DB, Khavari PA, Conley PB, Graves MK, Hansen LP, Admon A, Crabtree GR: Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. *Science (Washington DC)* 254: 1762–1767, 1991
 10. Citron BA, Davis MD, Milstien S, Gutierrez J, Mendel DB, Crabtree GR, Kaufman S: Identity of 4 α -carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins. *Proc Natl Acad Sci USA* 89: 11891–11894, 1992
 11. Hauer CR, Rebrin I, Thony B, Neuheiser F, Curtius HC, Hunziker P, Blau N, Ghisla S, Heizmann CW: Phenylalanine hydroxylase-stimulating protein/pterin-4 α -carbinolamine dehydratase from rat and human liver: Purification, characterization, and complete amino acid sequence. *J Biol Chem* 268: 4828–4831, 1993
 12. Blumenfeld M, Maury M, Chouard T, Yaniv M, Condamine H: Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. *Development* 113: 589–599, 1991
 13. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M: Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* 84: 575–585, 1996
 14. Ott MO, Rey-Campos J, Cereghini S, Yaniv M: vHnf1 is expressed in epithelial cells of distinct embryonic origin during development and precedes Hnf1 expression. *Mech Dev* 36: 47–58, 1991
 15. Coffinier C, Barra J, Babinet C, Yaniv M: Expression of the vHNF1/HNF1 β homeoprotein gene during mouse organogenesis. *Mech Dev* 89: 211–213, 1999
 16. Cereghini S, Ott MO, Power S, Maury M: Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryos suggest distinct and sequential developmental roles. *Development* 116: 783–797, 1992
 17. Coffinier C, Thepot D, Babinet C, Yaniv M, Barra J: Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. *Development* 126: 4785–4794, 1999
 18. Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S: Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. *Development* 126: 4795–4805, 1999
 19. Lazzaro D, De Simone V, De Magistris L, Lehtonen E, Cortese R: LFB1 and LFB3 homeoproteins are sequentially expressed during kidney development. *Development* 114: 469–479, 1992
 20. Berry CA, Rector FCJ: Renal transport of glucose, amino acids, sodium, chloride, and water. In: *The Kidney*, 4th Ed., Vol. 1, edited by Brenner MB, Rector FC Jr, Philadelphia, W. B. Saunders Co., 1991, pp 245–282
 21. Pontoglio M, Faust DM, Doyen A, Yaniv M, Weiss MC: Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene. *Mol Cell Biol* 17: 4948–4956, 1997
 22. Hediger MA, Coady MJ, Ikeda TS, Wright EM: Expression cloning and cDNA sequencing of the Na⁺/glucose co-transporter. *Nature (Lond)* 330: 379–381, 1987
 23. Kanai Y, Lee WS, You G, Brown D, Hediger MA: The human kidney low affinity Na⁺/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for D-glucose. *J Clin Invest* 93: 397–404, 1994
 24. You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA: Molecular characteristics of Na⁺-coupled glucose transporters in adult and embryonic rat kidney. *J Biol Chem* 270: 29365–29371, 1995
 25. Mackenzie B, Panayotova-Heiermann M, Loo DD, Lever JE, Wright EM: SAAT1 is a low affinity Na⁺/glucose cotransporter and not an amino acid transporter: A reinterpretation. *J Biol Chem* 269: 22488–22491, 1994
 26. Pontoglio M, Prié D, Cheret C, Doyen A, Leroy C, Froguel P, Velho G, Yaniv M, Friedlander G: HNF1 α controls renal glucose reabsorption in mouse and man. *Embo Rep* 2000, in press
 27. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI: Mutations in the hepatocyte nuclear factor-1 α gene in maturity-onset diabetes of the young (MODY3). *Nature (Lond)* 384: 455–458, 1996
 28. Vaxillaire M, Boccio V, Philippi A, Vigouroux C, Terwilliger J, Passa P, Beckmann JS, Velho G, Lathrop GM, Froguel P: A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. *Nat Genet* 9: 418–423, 1995
 29. Froguel P, Vaxillaire M, Velho G: Genetic and metabolic heterogeneity of maturity-onset diabetes of the young. *Diabetes Rev* 5: 123–130, 1997
 30. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A, Pick AJ, Baldwin A, Velho G, Froguel P, Levisetti M, Bonner-Weir S, Bell GI, Yaniv M, Polonsky KS: Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. *J Clin Invest* 101: 2215–2222, 1998
 31. Dukes ID, Sreenan S, Roe MW, Levisetti M, Zhou YP, Ostrega D, Bell GI, Pontoglio M, Yaniv M, Philipson L, Polonsky KS: Defective pancreatic β -cell glycolytic signaling in hepatocyte nuclear factor-1 α -deficient mice. *J Biol Chem* 273: 24457–24464, 1998
 32. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). *Nature (Lond)* 384: 458–460, 1996
 33. Stoffel M, Duncan SA: The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. *Proc Natl Acad Sci USA* 94: 13209–13214, 1997
 34. Vaxillaire M, Abderrahmani A, Boutin P, Bailleul B, Froguel P, Yaniv M, Pontoglio M: Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. *J Biol Chem* 274: 35639–35646, 1999
 35. Chouard T, Jeannequin O, Rey-Campos J, Yaniv M, Traincard F: A set of polyclonal and monoclonal antibodies reveals major differences in post-translational modification of the rat HNF1 and vHNF1 homeoproteins. *Biochimie* 79: 707–715, 1997